Dr. Andreadis on Response to CAR T-Cell Therapy

Charalambos (Babis) Andreadis, MD, MSCE
Published: Monday, Oct 15, 2018



Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses response to chimeric antigen receptor (CAR) T-cell therapy.

Response to CAR T-cell therapy may not be immediate, explains Andreadis, noting that a delayed partial response does not mean that the therapy failed. Based on the data surrounding axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah), physicians know that patients may take a long time to respond to CAR T cells.

Data have shown that patients may take up to 6 months to respond to axi-cel and up to 12 months with tisagenlecleucel. That response is mostly an imaging epiphenomenon rather than a biological delay, says Andreadis. PET scans can be positive for many reasons including inflammation and T-cell infiltration, adds Andreadis. Therefore, it is important to have some signs of clinical progression or some evidence by biopsy that there is actual disease left before therapy is abandoned or changed.
SELECTED
LANGUAGE


Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses response to chimeric antigen receptor (CAR) T-cell therapy.

Response to CAR T-cell therapy may not be immediate, explains Andreadis, noting that a delayed partial response does not mean that the therapy failed. Based on the data surrounding axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah), physicians know that patients may take a long time to respond to CAR T cells.

Data have shown that patients may take up to 6 months to respond to axi-cel and up to 12 months with tisagenlecleucel. That response is mostly an imaging epiphenomenon rather than a biological delay, says Andreadis. PET scans can be positive for many reasons including inflammation and T-cell infiltration, adds Andreadis. Therefore, it is important to have some signs of clinical progression or some evidence by biopsy that there is actual disease left before therapy is abandoned or changed.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x